The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

(2011) A Peasland et al.   BRITISH JOURNAL OF CANCER

Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs

(2011) Hiroko Onozuka et al.   CANCER SCIENCE

Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR

(2011) David W. Schoppy et al.   JOURNAL OF CLINICAL INVESTIGATION

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

(2011) Hedy L Kindler et al.   LANCET ONCOLOGY

Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs

(2011) Luis I. Toledo et al.   Molecular Oncology

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

(2011) Philip M Reaper et al.   Nature Chemical Biology

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

(2011) Matilde Murga et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

(2011) Luis I Toledo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner

(2010) O. Gilad et al.   CANCER RESEARCH

Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair

(2010) Meredith A. Morgan et al.   CANCER RESEARCH

Radiosensitization by Chir-124, a selective Chk1 inhibitor: Effects of p53 and cell cycle checkpoints

(2010) Yungan Tao et al.   CELL CYCLE

The ATR barrier to replication-born DNA damage

(2010) Andrés J. López-Contreras et al.   DNA REPAIR

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

(2010) Philip A. Philip et al.   JOURNAL OF CLINICAL ONCOLOGY

Advanced pancreatic carcinoma: current treatment and future challenges

(2010) Anastasios Stathis et al.   Nature Reviews Clinical Oncology

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

The role of radiotherapy in multimodal treatment of pancreatic carcinoma

(2010) Thomas B Brunner et al.   Radiation Oncology

The DNA-damage response in human biology and disease

(2009) Stephen P. Jackson et al.   NATURE

Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53

(2009) Yaroslava Ruzankina et al.   NATURE GENETICS

Epidemiology of pancreatic cancer: an overview

(2009) Sara Raimondi et al.   Nature Reviews Gastroenterology & Hepatology

Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity

(2008) R. Prevo et al.   CANCER RESEARCH

Single-Nucleotide Polymorphisms of DNA Damage Response Genes Are Associated with Overall Survival in Patients with Pancreatic Cancer

(2008) T. Okazaki et al.   CLINICAL CANCER RESEARCH

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE